Patent ID: 11932630
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 17:
18. A method of treatment of a disease and/or disorder mediated by LTA4H activity in a subject, wherein the method comprises administering to said subject a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease and/or disorder is selected from: acute or chronic inflammation, anaphylactic reactions, allergic reactions, atopic dermatitis, psoriasis, acute respiratory distress syndrome, immune complex-mediated pulmonary injury and chronic obstructive pulmonary disease, inflammatory bowel diseases, gastrointestinal ulcers, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), neutrophilic dermatoses, immune-complex-mediated glomerulonephritis, Hidradenitis suppurativa, autoimmune diseases, vasculitides, cardiovascular disorders, sepsis, inflammatory and neuropathic pain, periodontal disease, ear infections, migraine, benign prostatic hyperplasia, Sjogren-Larsson Syndrome and cancers.